[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular President and Director David B. Roberts reported option exercises and subsequent open-market sales on 08/11/2025. The Form 4 shows Mr. Roberts acquiring shares upon exercise of previously granted stock options and selling multiple blocks of common stock the same day.

The filing lists option exercises generating 3,979, 123 and 6,713 shares at exercise prices of $37.29 and $35.48. On 08/11/2025 he sold blocks of 3,718, 384 and 6,713 shares at weighted average prices of $92.5337, $91.5484 and $92.3549, respectively. The filing shows beneficial ownership of 17,976 shares following these transactions. The Form is signed by Nathan Ulrich on 08/13/2025 as submitted.

Positive

• Timely and detailed disclosure of option exercises and sales on Form 4, including weighted average prices and share counts
• Continued direct ownership is reported: the filing shows the reporting person still holds 17,976 shares after the transactions

Negative

• Substantial open-market sales on 08/11/2025 totaling 10,815 shares (3,718 + 384 + 6,713), reducing insider holdings
• Exercises followed by immediate sales on the same date, which reduced beneficial ownership from higher interim levels to 17,976 shares

Insights

Securities Analyst

TL;DR: Routine option exercises followed by same-day sales; total sale volume and final holdings are disclosed.

The Form 4 documents exercises of vested and partially vested options and concurrent open-market dispositions on 08/11/2025. The transactions include option exercises at strikes of $35.48 and $37.29 and sales at weighted average prices around $91.55–$92.53. These filings are material for transparency and show a reduction in insider beneficial ownership to 17,976 shares. The disclosure is timely and quantifies both the acquired and sold share counts and prices.

Corporate Governance Expert

TL;DR: Insider complied with Section 16 reporting; exercises and sales occurred the same date, reducing holdings.

The reporting person, identified as President and Director, filed a Form 4 reporting multiple option exercises and subsequent sales on the same date (08/11/2025). The filing specifies exact share counts, exercise prices, weighted average sale prices and resulting beneficial ownership (17,976 shares). From a governance perspective, the document provides required transparency but reflects a net decrease in the officer's direct stock position after the transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Director

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		M		3,979(1)	A	$37.29	21,955	D
Common Stock	08/11/2025		M		123(1)	A	$35.48	22,078	D
Common Stock	08/11/2025		S		3,718(2)	D	$92.5337	18,360	D
Common Stock	08/11/2025		S		384(3)	D	$91.5484	17,976	D
Common Stock	08/11/2025		M		6,713(1)	A	$37.29	24,689	D
Common Stock	08/11/2025		S		6,713(4)	D	$92.3549	17,976	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.48	08/11/2025		M			123	12/20/2019(5)	12/20/2026	Common Stock	123	$0	0	D
Stock Option (Right to Buy)	$37.29	08/11/2025		M			3,979	12/02/2020(6)	12/02/2027	Common Stock	3,979	$0	9,385	D
Stock Option (Right to Buy)	$37.29	08/11/2025		M			6,713	12/02/2020(6)	12/02/2027	Common Stock	6,713	$0	2,672	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $91.91 to $92.91. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

3. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $91.38 to $91.89. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

4. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $92.045 to $93.04. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

5. This option is fully vested and exercisable.

6. This option is exercisable and vests over a five-year period at a rate of 20% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining four years.

	/s/ Nathan Ulrich	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did David B. Roberts report on the LMAT Form 4?

The Form 4 reports option exercises and open-market sales executed on 08/11/2025, with resulting beneficial ownership of 17,976 shares.

How many shares were sold by the insider (LMAT) on 08/11/2025?

The filing shows sales of 3,718, 384 and 6,713 shares on 08/11/2025, totaling 10,815 shares.

At what prices were shares sold according to the Form 4?

Sales were executed at weighted average prices of $92.5337, $91.5484 and $92.3549 as disclosed in the filing.

What option exercise details are disclosed on the Form 4 for LMAT?

The filing shows exercises producing 3,979, 123 and 6,713 shares at strike prices of $37.29 and $35.48.

Who is the reporting person and what is their role at LMAT?

The reporting person is David B. Roberts, identified as President and Director of LeMaitre Vascular, Inc.

When was the Form 4 filed/signed?

Transactions are dated 08/11/2025 and the Form shows a signature dated 08/13/2025 by Nathan Ulrich on the submitted filing.